Abstract
We demonstrate here the capacity of erythroid cells to mediate long-term, systemic and therapeutic protein delivery in vivo. By targeting human factor IX (hFIX) expression to late-stage erythropoiesis, we achieve long-term hFIX secretion at levels significantly higher (>tenfold) than those obtained with an archetypal ubiquitous promoter in a mouse model of hemophilia B. Erythroid cell–derived hFIX is biologically active, resulting in phenotypic correction of the bleeding disorder. In addition to achieving high expression levels and resistance to transcriptional silencing, red cell–mediated protein delivery offers multiple advantages including immune tolerance induction, reduction of the risk of insertional oncogenesis and relative ease of application by either engrafting transduced hematopoietic stem cells or transfusing ex vivo–generated, stem cell–derived erythroid cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ganong, W.F. . Review of Medical Physiology, edn. 20 (Lange Medical Books/McGraw-Hill, New York, 2001).
Wang, L. et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. USA 94, 11563–11566 (1997).
Mannucci, P.M. & Tuddenham, E.G. The hemophilias—from royal genes to gene therapy. N. Engl. J. Med. 344, 1773–1779 (2001).
May, C. et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406, 82–86 (2000).
Kurachi, S., Hitomi, Y., Furukawa, M. & Kurachi, K. Role of intron I in expression of the human factor IX gene. J. Biol. Chem. 270, 5276–5281 (1995).
Woods, N.B. et al. Lentiviral-mediated gene transfer into haematopoietic stem cells. J. Intern. Med. 249, 339–343 (2001).
Challita, P.M. & Kohn, D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA 91, 2567–2571 (1994).
Liu, Y., Nelson, A.N. & Lipsky, J.J. Vitamin K-dependent carboxylase: mRNA distribution and effects of vitamin K-deficiency and warfarin treatment. Biochem. Biophys. Res. Commun. 224, 549–554 (1996).
Samakoglu, S. et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol. 24, 89–94 (2006).
Kootstra, N.A., Matsumura, R. & Verma, I.M. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol. Ther. 7, 623–631 (2003).
Evans, G.L. & Morgan, R.A. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc. Natl. Acad. Sci. USA 95, 5734–5739 (1998).
Moayeri, M., Hawley, T.S. & Hawley, R.G. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol. Ther. 12, 1034–1042 (2005).
Heim, D.A. & Dunbar, C.E. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. Immunol. Rev. 178, 29–38 (2000).
Bagley, J., Bracy, J.L., Tian, C., Kang, E.S. & Iacomini, J. Establishing immunological tolerance through the induction of molecular chimerism. Front. Biosci. 7, d1331–d1337 (2002).
Bennett, B., Check, I.J., Olsen, M.R. & Hunter, R.L. A comparison of commercially available adjuvants for use in research. J. Immunol. Methods 153, 31–40 (1992).
Herzog, R.W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 5804–5809 (1997).
Axelrod, J.H., Read, M.S., Brinkhous, K.M. & Verma, I.M. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc. Natl. Acad. Sci. USA 87, 5173–5177 (1990).
Rodriguez, M.H. et al. Expression of coagulation factor IX in a haematopoietic cell line. Thromb. Haemost. 87, 366–373 (2002).
Li, Q., Peterson, K.R., Fang, X. & Stamatoyannopoulos, G. Locus control regions. Blood 100, 3077–3086 (2002).
Kikuchi, J. et al. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J. Gene Med. 6, 1049–1060 (2004).
Tiede, A. et al. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther. 10, 1917–1925 (2003).
Hoeben, R.C. et al. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb. Haemost. 67, 341–345 (1992).
Bigger, B.W. et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther. 13, 117–126 (2006).
Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419 (2003).
Kohn, D.B., Sadelain, M. & Glorioso, J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 3, 477–488 (2003).
von Kalle, C., Baum, C. & Williams, D.A. Lenti in red: progress in gene therapy for human hemoglobinopathies. J. Clin. Invest. 114, 889–891 (2004).
Sadelain, M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther. 11, 569–573 (2004).
Giarratana, M.C. et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat. Biotechnol. 23, 69–74 (2005).
Ng, E.S., Davis, R.P., Azzola, L., Stanley, E.G. & Elefanty, A.G. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 106, 1601–1603 (2005).
Margaritis, P. et al. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J. Clin. Invest. 113, 1025–1031 (2004).
Acknowledgements
We thank Inder Verma for providing the C57BL/6-FIX−/− mice. This work was supported by National Institutes of Health grants HL66952, HL57612, CA59350 and CA08748; by the Leonardo Giambrone Foundation; and by Mr. William H. Goodwin, Mrs. Alice Goodwin and the Commonwealth Cancer Foundation for Research. A.H.C. is the recipient of a scholarship from the Program of Excellence in Gene Therapy (PEGT) program. M.T.S. is the recipient of a predoctoral fellowship from the Cancer Research Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Chang, A., Stephan, M. & Sadelain, M. Stem cell–derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol 24, 1017–1021 (2006). https://doi.org/10.1038/nbt1227
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1227
This article is cited by
-
Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
Nature Communications (2020)
-
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
Leukemia (2017)
-
De novo formed satellite DNA-based mammalian artificial chromosomes and their possible applications
Chromosome Research (2015)
-
Development of gene transfer for induction of antigen-specific tolerance
Molecular Therapy - Methods & Clinical Development (2014)
-
Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIXnull Mice
Molecular Therapy (2014)